Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus vandetanib versus gemcitabine plus placebo in advanced pancreatic cancer
ISRCTN74555382Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Sep 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vandetanib and gemcitabine in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC) and Anaplastic Pancreatic Carcinoma (APC), sponsored by University of Liverpool. Primary endpoint: Overall survival. Started Sep 2011; status: completed.
02
Drugs
vandetanibgemcitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)Anaplastic Pancreatic Carcinoma (APC)
Beyond the preview
Go deeper on ISRCTN74555382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74555382.